Search
Chugai Pharmaceutical, a member of the Roche Group, and Singapore-based biotechnology firm Gero have entered into a joint research and licensing agreement aimed at developing groundbreaking therapies for aging-related diseases. Pursuant to the agreement, Chugai will bear the initial costs and potentially disburse up to US$250 million in milestone payments to secure global exclusive rights for the development and commercialization of the targeted therapies. Both parties will synergize Gero's AI platform with Chugai's advanced antibody engineering technology to create novel antibody drug candidates. This strategic collaboration is poised to expedite the development of innovative treatments addressing age-related diseases and functional decline.
-
C114 Communication Network -
Communication Home
